Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Delta 9 Cannabis Inc. (T:DN)

Business Focus: Pharmaceuticals

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: Osborne Village
PO Box 68096
Tel: N/A
IR: See website
Key People
Nitin Kaushal
Chairman of the Board
John William Arbuthnot
Chief Executive Officer, Director
James Lawson
Chief Financial Officer
Business Overview
Delta 9 Cannabis Inc , formerly SVT Capital Corp, is a Canada-based company engaged in Biotechnology & Medical Research. The principal activities of The Company are the production, storage and sale of medical marijuana.
Financial Overview
For the six months ended 30 June 2021, Delta 9Cannabis Inc revenues increased 21% to C$30M. Net losstotaled C$5.7M vs. income of C$3.1M. Revenues reflectRevenue from Sale of Cannabis increase of 58% to C$29.3M.Net loss reflects FV Adjustments on Biological Assetsincrease of 86% to C$9.3M (expense), General andadministrative - Balancing increase from C$1.6M to C$3.9M(expense).
Employees: 192 as of Dec 31, 2020
Reporting Currency: Canadian Dollars
Enterprise value: $68.56M as of Jun 30, 2021
Annual revenue (TTM): $57.26M as of Jun 30, 2021
EBITDA (TTM): $0.31M as of Jun 30, 2021
Net annual income (TTM): -$15.19M as of Jun 30, 2021
Free cash flow (TTM): -$6.18M as of Jun 30, 2021
Net Debt Last Fiscal Year: $30.25M as of Jun 30, 2021
Shares outstanding: 104,897,268 as of Sep 2, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization